Literature DB >> 16366602

A new bisintercalating anthracycline with picomolar DNA binding affinity.

José Portugal1, Derek J Cashman, John O Trent, Neus Ferrer-Miralles, Teresa Przewloka, Izabela Fokt, Waldemar Priebe, Jonathan B Chaires.   

Abstract

A new bisintercalating anthracycline (WP762) has been designed, in which monomeric units of daunorubicin have been linked through their amino groups on the daunosamine moieties using an m-xylenyl linker. Differential scanning calorimetry and UV melting experiments were used to measure the ultratight binding of WP762 to DNA. The binding constant for the interaction of WP762 with herring sperm DNA was determined to be 7.3 (+/-0.2) x 10(12) M(-1) at 20 degrees C. The large favorable binding free energy of -17.3 kcal mol(-1) was found to result from a large negative enthalpic contribution of -33.8 kcal mol(-1) and an opposing entropic term (-TDeltaS = +16.5 kcal mol(-1)). A comparative molecular modeling study rationalized the increased binding by the m-xylenyl linker of WP762 positioning in the DNA minor groove compared to the p-xylenyl linker found in WP631, the first bis-anthracycline of this type. The cytotoxicity of WP762 was compared to that of other anthracyclines in Jurkat T lymphocytes. These studies, together with an analysis of the cell-cycle traverse in the presence of WP762, suggest that in these cells the new drug is more cytotoxic than the structurally related WP631.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16366602      PMCID: PMC2522373          DOI: 10.1021/jm050902g

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  36 in total

1.  Bisanthracycline WP631 inhibits basal and Sp1-activated transcription initiation in vitro.

Authors:  B Martín; A Vaquero; W Priebe; J Portugal
Journal:  Nucleic Acids Res       Date:  1999-09-01       Impact factor: 16.971

Review 2.  Sequence-specific DNA recognition by polyamides.

Authors:  P B Dervan; R W Bürli
Journal:  Curr Opin Chem Biol       Date:  1999-12       Impact factor: 8.822

3.  Ultratight DNA binding of a new bisintercalating anthracycline antibiotic.

Authors:  F Leng; W Priebe; J B Chaires
Journal:  Biochemistry       Date:  1998-02-17       Impact factor: 3.162

Review 4.  Dissecting the free energy of drug binding to DNA.

Authors:  J B Chaires
Journal:  Anticancer Drug Des       Date:  1996-12

5.  Structure of a DNA-bisdaunomycin complex.

Authors:  G G Hu; X Shui; F Leng; W Priebe; J B Chaires; L D Williams
Journal:  Biochemistry       Date:  1997-05-20       Impact factor: 3.162

6.  Binding of two novel bisdaunorubicins to DNA studied by NMR spectroscopy.

Authors:  H Robinson; W Priebe; J B Chaires; A H Wang
Journal:  Biochemistry       Date:  1997-07-22       Impact factor: 3.162

Review 7.  A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin.

Authors:  D A Gewirtz
Journal:  Biochem Pharmacol       Date:  1999-04-01       Impact factor: 5.858

8.  Structure-based design of a new bisintercalating anthracycline antibiotic.

Authors:  J B Chaires; F Leng; T Przewloka; I Fokt; Y H Ling; R Perez-Soler; W Priebe
Journal:  J Med Chem       Date:  1997-01-31       Impact factor: 7.446

9.  Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin.

Authors:  C A Frederick; L D Williams; G Ughetto; G A van der Marel; J H van Boom; A Rich; A H Wang
Journal:  Biochemistry       Date:  1990-03-13       Impact factor: 3.162

Review 10.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

Authors:  D J Booser; G N Hortobagyi
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

View more
  8 in total

1.  Tuning the DNA conformational perturbations induced by cytotoxic platinum-acridine bisintercalators: effect of metal cis/trans isomerism and DNA threading groups.

Authors:  Jayati Roy Choudhury; Rajsekhar Guddneppanavar; Gilda Saluta; Gregory L Kucera; Ulrich Bierbach
Journal:  J Med Chem       Date:  2008-05-06       Impact factor: 7.446

2.  Evaluation of molecular descriptors for antitumor drugs with respect to noncovalent binding to DNA and antiproliferative activity.

Authors:  José Portugal
Journal:  BMC Pharmacol       Date:  2009-09-16

3.  Synthesis and DNA-binding affinity studies of glycosylated intercalators designed as functional mimics of the anthracycline antibiotics.

Authors:  Wei Shi; Robert S Coleman; Todd L Lowary
Journal:  Org Biomol Chem       Date:  2009-07-17       Impact factor: 3.876

4.  Study on the interaction between the 1,4,5,8-naphthalene diimide-spermine conjugate (NDIS) and DNA using a spectroscopic approach and molecular docking.

Authors:  Zhiyong Tian; Hailong Cui; He Liu; Jun Dong; Huanyang Dong; Luyao Zhao; Xueting Li; Yan Zhang; Yingying Huang; Lina Song; Longxiang Bian; Yuxia Wang; Xuejun Xu; Chaojie Wang
Journal:  Medchemcomm       Date:  2017-09-26       Impact factor: 3.597

5.  The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds.

Authors:  Brian B Hasinoff; Hong Liang; Xing Wu; Lynn J Guziec; Frank S Guziec; Kyle Marshall; Jack C Yalowich
Journal:  Bioorg Med Chem       Date:  2008-01-26       Impact factor: 3.641

6.  Subtle recognition of 14-base pair DNA sequences via threading polyintercalation.

Authors:  Amy Rhoden Smith; Brian A Ikkanda; Garen G Holman; Brent L Iverson
Journal:  Biochemistry       Date:  2012-05-18       Impact factor: 3.162

7.  POT1 stability and binding measured by fluorescence thermal shift assays.

Authors:  Lynn W DeLeeuw; Robert C Monsen; Vytautas Petrauskas; Robert D Gray; Lina Baranauskiene; Daumantas Matulis; John O Trent; Jonathan B Chaires
Journal:  PLoS One       Date:  2021-03-30       Impact factor: 3.240

8.  Entropically-driven binding of mithramycin in the minor groove of C/G-rich DNA sequences.

Authors:  Francisca Barceló; Claudia Scotta; Miguel Ortiz-Lombardía; Carmen Méndez; José A Salas; José Portugal
Journal:  Nucleic Acids Res       Date:  2007-03-16       Impact factor: 16.971

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.